$MYGN
Myriad Genetics Inc
XNAS•Health Care•In Vitro & in Vivo Diagnostic Substances
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateMyriad Genetics Inc
XNAS•Health Care•In Vitro & in Vivo Diagnostic Substances
Why is MYGN down today? It is at $4.12 (-4.41%), and our scanner flagged it 93 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment MYGN spikes, and full due diligence on MYGN — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $MYGN 93 times in the last 30 days. Create a free account to track $MYGN, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
MYGN is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 4 unusual-volume and momentum alerts on MYGN today, peaking at 18.6x its normal volume.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Wheeler Benjamin Richard Officer | Sold (automatic/other) | -3K | sold 0.9% | 287K | $10K at $4.01 | Sep 21, 26 |
Sikri Vishal Officer | Acquired (grant/award) | +258K 0.3% of company | added 100% | 351K | n/a | Sep 16, 26 |
Fox Jennifer Lynne Officer | Sold (automatic/other) | -4K | sold 1.4% | 306K | $14K at $3.23 | Sep 3, 26 |
Wheeler Benjamin Richard Officer | Sold (automatic/other) | -9K | sold 2.9% | 290K | $27K at $3.03 | Aug 16, 26 |
Donnelly Brian J Officer | Acquired (grant/award) | +5K | added 0.9% | 573K | $20K at $3.94 | Jun 11, 26 |
Raha Samraat S. Officer | Acquired (grant/award) | +4K | added 0.3% | 1.07M | $14K at $3.94 | Jun 11, 26 |
Kumar Rashmi Director | Sold (automatic/other) | -15K 0.02% of company | sold 8.0% | 172K | $67K at $4.46 | Jun 8, 26 |
Bisaro Paul Director | Acquired (grant/award) | +60K 0.06% of company | added 61% | 157K | n/a | Jun 4, 26 |
Kumar Rashmi Director | Acquired (grant/award) | +60K 0.06% of company | added 47% | 187K | n/a | Jun 4, 26 |
Dreismann Heinrich Director | Acquired (grant/award) | +60K 0.06% of company | added 35% | 231K | n/a | Jun 4, 26 |
Reitan Colleen F Director | Acquired (grant/award) | +60K 0.06% of company | added 65% | 152K | n/a | Jun 4, 26 |
Phanstiel S. Louise Director | Acquired (grant/award) | +60K 0.06% of company | added 21% | 342K | n/a | Jun 4, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in in vitro & in vivo diagnostic substances, closest in size first.
MYGN is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 4 unusual-volume and momentum alerts on MYGN today, peaking at 18.6x its normal volume.
MYGN last traded at $4.12, down 4.41% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Myriad Genetics Inc (MYGN) is next expected to report earnings on Monday, November 2, 2026, about 21 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The MYGN Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged MYGN 93 times in the last 30 days.
MYGN (Myriad Genetics Inc) trades on XNAS, with a market cap of about $412M in the In Vitro & In Vivo Diagnostic Substances sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge MYGN for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$MYGN discussion
Sign in to ask a question or join the discussion.